Melting Point: 106-108°C (alternatively reported as 107.0-110.0°C)
Density: 1.2±0.1 g/cm³
Boiling Point: 616.2±55.0 °C at 760 mmHg
Flash Point: 326.4±31.5 °C
Vapor Pressure: 0.0±1.9 mmHg at 25°C
Refractive Index: 1.556
Safety Information
Personal Protective Equipment (PPE): Recommended PPE includes protective eyewear (e.g., meeting NIOSH or EN 166 standards), gloves (conforming to EU 89/686/EEC regulations and EN 376 standards), and respiratory filters of N95 (US) or P1 (EN143) rating.
Hazard Codes (Europe): Xi
Risk Statements (Europe): R36/38 (Irritating to eyes and skin)
Safety Statements (Europe): S26 (In case of contact with eyes, rinse immediately with plenty of water and seek medical advice); S37/39 (Wear suitable gloves and eye/face protection)
Product Applications
Ramipril is primarily used for the treatment of hypertension. It is also indicated for the management of congestive heart failure and acute myocardial infarction (MI) with left ventricular dysfunction occurring within the first few days after the acute MI. The drug can be taken with or without food, and the daily dose can be administered in a single dose or divided into two doses (morning and evening) depending on the indication and dosing requirements. The addition of diuretics may enhance the antihypertensive effect of Ramipril.
Synthetic Route
The synthesis of Ramipril involves multiple steps, including esterification, acylation, hydrogenation, and other reactions, ultimately yielding the desired Ramipril crystal with specific configuration and biological activity.
In summary, Ramipril (CAS 87333-19-5) is a crucial antihypertensive medication with well-defined physicochemical properties and extensive clinical applications.
